share_log

Arcutis Biotherapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

SEC announcement ·  Mar 5 06:47
Summary by Futu AI
Arcutis Biotherapeutics, Inc. officer David W. Osborne is set to sell 4,255 shares of common stock on 03/04/2024, as per the latest filing. The shares to be sold were recently acquired through restricted stock vests on three separate dates: 882 shares on 03/03/2024, 2,618 shares on 03/01/2024, and 755 shares on 02/27/2024, all from Arcutis Biotherapeutics. The aggregate market value of the shares to be sold is reported at $47,320.81. There is no transaction history reported for the past three months prior to this notice.
Arcutis Biotherapeutics, Inc. officer David W. Osborne is set to sell 4,255 shares of common stock on 03/04/2024, as per the latest filing. The shares to be sold were recently acquired through restricted stock vests on three separate dates: 882 shares on 03/03/2024, 2,618 shares on 03/01/2024, and 755 shares on 02/27/2024, all from Arcutis Biotherapeutics. The aggregate market value of the shares to be sold is reported at $47,320.81. There is no transaction history reported for the past three months prior to this notice.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.